Press Releases | Adaptive Biotechnologies

Skip to main navigation

Overview(current)

Stock
Stock Quote & Chart
Analyst Coverage

Governance
Leadership
Board of Directors
Committee Composition
Governance Documents

SEC Filings(current)

News & Events
Press Releases
Events
Presentations

Resources
Frequently Asked Questions
Email Alerts
Investor Contact

Press Releases

Looking for media resources?
Please visit our media resource center.

Year

Adaptive Biotechnologies and Collaborators to Present 28 Studies at ASH 2018 That Support the Use of the clonoSEQ® Assay to Detect and Monitor Minimal Residual Disease in Patients with Blood Cancers

12-01-2018 at 5:00 PM EST
FDA Grants De Novo Designation for Adaptive Biotechnologies’ clonoSEQ Assay to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia

09-28-2018 at 5:00 PM EDT
A New Study Published in the Journal Blood Demonstrates that Measuring Minimal Residual Disease Negativity Using Adaptive Biotechnologies’ Next-Generation Sequencing Platform is a Major Predictive Indicator in Multiple Myeloma

09-28-2018 at 5:00 PM EDT
Adaptive Biotechnologies Announces a Collaboration With Sanofi to use Adaptive’s clonoSEQ® Assay to Measure Minimal Residual Disease in Active and Future Isatuximab Multiple Myeloma Trials

05-29-2018 at 5:00 PM EDT
FDA Approves First Therapy for Patients With MRD-Positive ALL

04-02-2018 at 5:00 PM EDT
Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics Executive Michael Pellini, MD, to Board of Directors

02-13-2018 at 5:00 PM EST
Adaptive Biotechnologies Announces Partnership with Microsoft to Decode the Human Immune System to Improve the Diagnosis of Disease

01-04-2018 at 5:00 PM EST
Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017

12-08-2017 at 5:00 PM EST
Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ Assay in Multiple Myeloma

11-06-2017 at 5:00 PM EST
Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting

07-27-2017 at 5:00 PM EDT

Displaying 151 - 160 of 164

Pagination

First page
Previous page
…
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Current page 16
Page 17
Next page
Last page

Print Page
RSS Feeds
Contacts

email

Keep up to date with Adaptive

Sign up to receive our press releases via email

© Adaptive Biotechnologies. All Rights Reserved. Legal & Privacy

Privacy Policy | Cookie Policy | Notice at Collection | Do Not Sell or Share My Info (CA Residents) | Terms of Service | Code of Conduct

© Adaptive Biotechnologies. All Rights Reserved. Legal & Privacy